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ScienceDirectBluetongue virus (BTV) reverse genetics (RG), available since
2007, has allowed the dissection of the virus replication cycle,
including discovery of a primary replication stage. This
information has allowed the generation of Entry-Competent-
Replication-Abortive (ECRA) vaccines, which enter cells and
complete primary replication but fail to complete the later
stage. A series of vaccine trials in sheep and cattle either with a
single ECRA serotype or a cocktail of multiple ECRA serotypes
have demonstrated that these vaccines provide complete
protection against virulent virus challenge without cross-
serotype interference. Similarly, an RG system developed for
the related African Horse Sickness virus, which causes high
mortality in equids has provided AHSV ECRA vaccines that are
protective in horses. ECRA vaccines were incapable of
productive replication in animals despite being competent for
cell entry. This technology allows rapid generation of emerging
Orbivirus vaccines and offers immunogenicity and safety levels
that surpass attenuated or recombinant routes.
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Introduction
Virus reverse genetics (RG) techniques are based on the
ability to rescue viable virus containing designed genetic
changes. The role of those changes in virus replication or
pathogenicity can then be assessed. The technique relies
on the transfection of cells with nucleic acids encoding
the viral genome, or mutants thereof, and was developed
first for DNA viruses and subsequently for positive-sense
RNA viruses. Gradually reverse genetics technology has
been developed for all the major virus families. The
techniques have particularly become the method of
choice for the design of efficacious and safe vaccines withwww.sciencedirect.com specific changes in viral components added to induce
strong protective immunity in the host without health
risks or deleterious effects.
In contrast to the development of RG systems for positive
and negative strand RNA viruses, the development of RG
systems for double-stranded RNA (dsRNA) viruses of the
Reoviridae family was relatively slow, with the first two
Reoviridae RG systems, for Bluetongue virus (BTV) and
reovirus, not having been developed until 2007 [1,2].
They were, nevertheless, brought to fruition and in the
last decade these systems have enabled remarkable prog-
ress in the understanding of the replication process and
pathogenesis of these viruses. Further, RG systems have
been used successfully to develop attenuated vaccine
strains for 2 different Orbiviruses, BTV and the closely
related African Horse sickness virus (AHSV).
BTV and AHSV are insect-vectored emerging pathogens
of wild and domestic animals which have a severe eco-
nomic impact on the worldwide agricultural industry.
BTV causes disease in ruminants, for example, sheep,
goat, and cattle, with a mortality rate of up to 70% in
certain breeds of animals. It is endemic in many tropical
and subtropical countries and represents an ongoing
threat to livestock in both developed and developing
countries. AHSV is one of the most devastating diseases
of horses characterized by high fever, respiratory distress,
lethargy, and has an extremely high mortality rate (up to
90%). Both viruses are transmitted by the same insect
vector, the Culicoides midge, and thus there is the poten-
tial for AHSV outbreaks anywhere in the world, similar to
recent BTV outbreaks in Europe [3,4]. Current commer-
cially available live virus vaccines against these viruses are
considered neither safe nor sufficiently effective to be
used widely. These issues are further compounded by the
existence of multiple serotypes of these viruses, 27 for
BTV, and 9 for AHSV. Therefore, rationally designed safe
vaccine strains that protect against these viruses are
highly desirable.
Bluetongue virus and development of revere
genetics
The virion is a non-enveloped icosahedral particle com-
posed of three concentric protein layers enclosing a seg-
mented genome of 10 linear dsRNA molecules (S1-S10)
(Reviewed [5,6]). The outercapsid, composed of two major
structural proteins, VP2 and VP5, is involved in cell attach-
ment and membrane penetration during the initial stages of
infection [7–9]. The receptor attachment protein, VP2, isCurrent Opinion in Virology 2020, 44:35–41
36 Preventive and therapeutic vaccinesthe serotype determinant and is the most variable viral
protein [10,11]. After entry, the outer layer of the virion
particle is uncoated in the endosome prior to the release of
the remaining core particle into the cytoplasm of the host
cell [12]. The core particle is made up of two concentric
protein layers, the surface VP7 layer and an underlying VP3
layer, which surrounds the genomic dsRNA segments
together with the replicase complex of three enzymatic
minor proteins, VP1, VP4, and VP6 [13,14]. While the viral
genomic dsRNAs never leave the core particle, the core
particle itself is transcriptionally active, synthesizing and
extruding multiple capped single-stranded mRNA copies
of each viral genome segment into the host cell cytoplasm
[15,16]. These transcripts have the dual roles of encoding
the 11 viral proteins (seven structural and four nonstruc-
tural) and serving as templates for the synthesis of the new
viral dsRNA segments. As defined by the Baltimore classi-
fication scheme, all viruses, including complex viruses such
as BTV replicate via the production of a unique set of viral
transcripts and that viral single-stranded RNAs (ssRNAs),Figure 1
(a) (b) 
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The reverse genetics system and its use to generate ECRA vaccines. (a) Al
any genetic changes to be introduced into the virus. (b) Transfection of cell
(c) Characterization of the genomes of rescued viruses shows them to have
(d) The infectivity and VP6 helper cell line dependency of the ECRA virus. (e
EM of ECRA viral core particles. Note the lack of a genome as a consequen
Current Opinion in Virology 2020, 44:35–41 delivered to the host cell cytoplasm by transfection should
allow both critical functions of virus RNA, translation and
replication, to be achieved. Thus, to develop BTV RG, the
possibility of recovering infectious BTV following the
transfection of permissive cells with BTV transcripts
(ssRNAs) was assessed. Transfection of 10 BTV transcripts
synthesized in vitro using BTV core particles was indeed
found to be sufficient to establish BTV infection in per-
missive cells [2]. Subsequently, the recovery of BTV
entirely from in vitro synthesized T7 transcripts, derived
from cDNA clones, was investigated and found to be a
viable means of generating BTV with a fully defined
genome (Figure 1) [17]. This method permits the recovery
of mutants in a consistent genetic background with no
screening required to remove wild-type virus. The ability
to generate specific mutants provides a robust tool not only
to investigate the different stages of BTV replication cycle
but also for the generation of specifically modified vaccines
for BTV that are both non-transmissible and highly
efficacious.(c)
(f)
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s with all 10 transcripts results in virus recovery and plaque formation.
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ce of the deletion of VP6.
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A modified virus recovered from cloned genes should
facilitate the rapid generation of defined attenuated vac-
cine strains. One class of these are ECRA (Entry Com-
petent Replication Abortive) viruses, formally known as
‘DISC’ viruses. These strains can enter BTV-permissive
cells, disassemble, and synthesise viral proteins, but are
incapable of replication due to the lack of an essential
gene product. However, the modified strains still trigger
an innate immune response and the subsequent develop-
ment of neutralizing antibodies. Such viruses are incapa-
ble of producing infectious virions unless the deleted
function is provided in trans by a complementing cell line.
To this end, we targeted an essential component of
primary replicase complex, VP6 which is responsible
for the ssRNA packaging into the capsid and is believed
to assist in unwinding the duplex RNAs [18,19]. A series
of BTV-1 mutant viruses targeting VP6 [18], were rescued
by RG and then examined for their capacity to replicate
both in wild-type cells and in a VP6-expressing cell line
[19]. Characterization of the growth properties of mutant
viruses showed that each mutant had the necessary char-
acteristics for a potential vaccine strain: (i) viral protein
expression in non-complementing mammalian cells, (ii)
no infectious virus generated in non-complementing
cells, and (iii) efficient replication in the complementing
VP6 cell line (Figure 1).
To assess VP6 RG viruses as vaccine candidates, two VP6-
deletion mutant viruses, were used to vaccinate two groups
of six sheep, each injected subcutaneously between
5  106 to 1  107 PFU and a group of animals was
inoculated with VP6-complementing cell lysate as control
[19]. Animals were boosted with the same vaccineFigure 2
Trial data of two ECRA vaccine candidates. Left: Neutralizing antibody titre
Viremia detected by RT-PCR of the BTV genome. The low level transient po
www.sciencedirect.com preparations or VP6-cell lysate 21 days after the first vacci-
nation and blood and serum samples were collected at
regular intervals to monitor virus replication and the
immune response. All vaccinated animals seroconverted
by 7 days post-vaccination, in contrast to the control group
where no specific anti-BTV antibodies were detected.
Further, all immunized animals produced a neutralizing
response suggesting that the two VP6 deletion viruses were
capable of inducing BTV antibody responses in the vacci-
nated animals (Figure 2). Whether the elicited antibodies
were sufficient to protect the vaccinated sheep against
virulent virus, was subsequently assessed by challenge with
BTV-1 at 42 days post-vaccination and blood samples were
taken at regular intervals. All samples were tested for both
group-specific protein VP7 antibodies by ELISA using and
for type-specific neutralizing antibody titres. Vaccinated
animals displaced a sustained antibody response through-
out the experiment by both ELISA and titre, whereas the
control animals only developed group-specific and neutral-
izing antibodies after challenge. More importantly, BTV-
specific quantitative real-time RT-PCR test of blood sam-
ples of each animal failed to detect any genomic RNA in
vaccinated animals (Figure 2), confirming the absence of
BTV replication throughout the vaccination trial study.
Rapid generation of a reassortant ECRA
vaccine strain and its protective immune
response in sheep
Since the BTV ‘core’ elements are conserved, the same
core can be used for generating vaccines for new sero-
types simply by substituting the outer capsid protein
genes. Indeed, it was possible to rapidly generate a
reassortant ECRA virus that consisted of the BTV-1 core
with the outer capsid proteins, VP2 (serotype determi-
nant) and VP5, of BTV-8 (BTV-1/8D1) a highlyCurrent Opinion in Virology
s following prime, boost and challenge with virulent BTV. Right:
sitivity from day 20 in the ECRA 1 sample is the input vaccine sample.
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38 Preventive and therapeutic vaccinespathogenic serotype, by transfecting cells with the VP2
and VP5 encoding RNA segments of BTV 8, together
with the remaining eight segments from the replication
defective BTV1 [19]. The protective capabilities of this
reassortant BTV-8 ECRA virus were assessed in sheep by
challenge with a virulent BTV-8 strain as described for
the BTV-1 ECRA vaccine strain. The data demonstrated
conclusively that this vaccine was highly protective and
could offer a promising alternative to the currently avail-
able attenuated and killed virus vaccines. The vaccines
are also DIVA compliant (differentiating infected from
vaccinated animals) as the lack of VP6 is a distinguishing
feature of the vaccine but not the true infection.
Protective efficacy of monovalent and
multivalent BTV ECRA vaccine strains in
sheep and cattle against virulent virus
challenge
The success and ease of vaccine generation for BTV-1/8
strain was then extended by exchanging the two RNA
segments responsible for serotype determination to gen-
erate a series of monovalent ECRA vaccine strains for
different BTV serotypes, including the European sero-
types that have caused serious disease in animals. Accord-
ingly, reassortant ECRA viruses were generated for six
different BTV serotypes (BTV-2, BTV-4, BTV-10, BTV-
13, BTV-21, and BTV-24) by substituting segments S2
and S6 (encoding VP2 and VP5, respectively) and fully
characterized as described above [20]. The immunoge-
nicity of each of these was then assessed in cattle.
Naı̈ve heifers (3 in each group) between 9 and 18 months
of age were vaccinated with one of ECRA BTV-2, BTV-4,
or BTV-8, in two doses administered 21 days apart. A
further nine received a lysate of complementary cells as
controls. Clinical score and rectal temperature were taken
daily from 4 days before the first vaccination (V1) until the
end of the challenge experiment (day 63). Serum samples
were taken at regular intervals from day 4–21 days after
both the first and second vaccinations. 42 days post
vaccination, vaccinated animals and three controls were
challenged by subcutaneous delivery of 4  105 TCID50
of a virulent BTV strain of the homologous serotype.
Whole-blood samples of post-challenged animals were
taken at regular intervals and serum samples were
collected at 0-days and 21-days post challenge. All vacci-
nated animals had neutralizing antibodies against homol-
ogous serotypes and virus replication was not detectable
in the vaccinated animal samples post challenge, in
contrast to the control animal samples.
Simultaneous circulation of two or more serotypes of BTV
emphasizes the necessity of a vaccine that protects
against several serotypes. Working toward the develop-
ment of a multiserotype vaccine, similar to the three
polyvalent, live attenuated vaccines currently in use in
South Africa, a cocktail mixture of six ECRA virusesCurrent Opinion in Virology 2020, 44:35–41 (BTV-1, BTV-2, BTV-4, BTV-8, BTV-13 and BTV-
21), all identified in European outbreaks [4], was also
assessed [20]. Three groups of six sheep were inoculated
with the cocktail vaccine (14  105 PFU/strain) in a
prime and boost protocol. One group of nine sheep
received an equivalent dose of cell lysate and served as
the control group. Blood samples were collected at regular
intervals over the experimental period to determine the
serological response to vaccination and for detection of
virus replication. In parallel, body temperatures, as a sign
of disease, were recorded routinely for all groups.
All animals vaccinated with the cocktail vaccine had
neutralizing antibodies against all the serotypes included
(BTV-1, BTV-2, BTV-4, BTV-8, BTV-13, and BTV-21)
and there was no apparent interference with respect to the
ability of the animal to respond to each of the vaccine
strains present in the cocktail suggesting that, in practice,
such a cocktail vaccine would be able to protect animals
against all included serotypes. On day 42, each group of
vaccinated sheep and three control sheep were chal-
lenged with virulent viruses, either BTV-2 or BTV-4 or
BTV-8, and monitored for a further 21 days (Figure 3).
After challenge, none of the vaccinated animals had dis-
ease symptoms irrespective of the vaccine given, mono-
valent or multivalent, whereas all control animals showed
severe clinical signs associated with bluetongue disease
(Figure 3). Further vaccinated animals had no sign of virus
replication, in contrast to all the control animals which
showed virus replication as expected. Moreover, in a
subsequent study, when groups of sheep were vaccinated
with a cocktail of six different vaccines similarly and
challenged at 21 days (early) or 154 days (5 months, late)
post-vaccination with virulent viruses, all vaccinated ani-
mals, both in the early challenge or the late challenge
group, were protected and had no signs of clinical disease.
Protection was also achieved in cattle either with mono-
valent ECRA vaccine strains or a cocktail of three vaccine
strains, albeit at a lesser level than in sheep.
To advance the ECRA vaccines to the marketplace, a
number of parameters were tested for their effect on
vaccine performance, such as the genetic stability of vac-
cine strains and the complementing cell line, and optimal
storage conditions, including additives, temperature, and
desiccation [21]. These are all necessary for the protective
capacity to be maintained following synthesis at industrial
scale. In compliance with the manufacturing requirements
of vaccine formulations without antibiotics, we found that
the complementing VP6 cell line maintained a constant
level of VP6 expression even at high passage numbers and
in the absence of the selective agent (puromycin) in the
growth media. Altogether, our data showed that the ECRA
vaccine strains are genetically stable, and that virus titre can
be maintained by desiccation in the presence of stabilizingwww.sciencedirect.com
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Performance of an ECRA cocktail vaccine of 6 BTV strains as indicated. (a) Neutralizing antibody responses of animals. Each column represents
the average titres of six animals of each test group or three animals of each control group to the six individual BTV strains as indicated (modified
from Figure 5 of Celma et al. [20]). The threshold for the assay was 8. (b) Body temperature as a marker of clinical signs recorded in animal
groups post challenge with BTV-2, or BTV-4 or BTV-8.reagents. These features are essential for mass production
and vaccine administration in the field as no cold chain for
delivery and handling is needed.
In addition, the ease of effective ECRA vaccine develop-
ment using the RG systemwill facilitate the inclusionofnew
serotypes in existing vaccination programs. In this manner, awww.sciencedirect.com very-rapid-response vaccine could be developed based on
which serotypes are circulating in the population at the time
of an outbreak.
A further type of live-attenuated BTV vaccine has also
been described. In this, the BTV virus is rescued in the
absence of the gene encoding non-structural proteinsCurrent Opinion in Virology 2020, 44:35–41
40 Preventive and therapeutic vaccinesNS3/NS3a which is involved in virus egress and host
interaction. The result is an attenuated strain named a
Disabled Infectious Single Animal (DISA) vaccine.
However, unlike ECRA, DISA vaccines are capable of
low-level replication leaving one the possibility of the
reacquisition of NS3 type functions from the host or a
concurrent virus infection. Nevertheless, vaccine studies
with DISA vaccines have shown protection in vaccinated
animals and an inability to replicate in the Culicoides
vector, which would likely block animal transmission
[22,23].
AHSV RG-based vaccines that protect horses
from African horse sickness disease
AHSV which is transmitted by biting midges similar to
BTV causes severe disease in equids, with 95% mortality
in naı̈ve horses. Therefore, the development of efficient
vaccines could be extremely important to counter the
major economic losses caused by AHSV outbreaks in the
equine industry. To this end and using the experience
for BTV RG vaccines as an exemplar, we established a
highly efficient RG system for AHSV serotype 1
(AHSV1) and, subsequently, a VP6-defective AHSV1
strain in combination with in trans complementation
of AHSV VP6 [24–26]. This was then used to generate
ECRA viruses for all nine serotypes, which required the
exchange of two to five RNA segments to achieve
equivalent titres of particles. All reassortant ECRA
viruses could be amplified and propagated to high titres
in cells complemented with VP6 but were wholly unable
to replicated in any other cells. Initially, their protective
efficacy was established using a model animal, the type I
interferon receptor (IFNAR)-knockout mouse. These
data were positive and subsequently, one monovalent
(ECRA.A4) vaccine strain of AHSV4 and multivalent
cocktail (ECRA.A1/4/6/8) vaccine strains of AHSV1, 4, 6,
and 8 were tested in ponies [27]. Two groups of four
ponies were inoculated with each vaccine, and two
ponies with control lysate, and two weeks after the
booster vaccination all animals were challenged with
virulent AHSV4, the most pathogenic virus of the ser-
otypes used. In contrast to the control animals, all
vaccinated ponies were protected and did not develop
severe clinical symptoms of AHS. Furthermore, the
multivalent cocktail vaccinated ponies produced neu-
tralizing antibodies against all serotypes present in the
cocktail, and a foal born during the trial was healthy and
had no viremia. These results validate the suitability of
these ECRA strains as a new generation of vaccines for
AHSV.
Two further vaccine trials were undertaken in ponies: (1)
to measure the duration of the antibody response of
ECRA vaccine strain for up to 6 months and (2) to
determine if all nine vaccine strains could be segregated
into prime and boost regimes for achieving protective
neutralizing antibodies against all serotypes.Current Opinion in Virology 2020, 44:35–41 For the duration study, a monovalent ECRA AHSV4
strain was used as both prime and boost vaccine and
for the cocktail vaccines, ponies were vaccinated with
AHSV 1/4/7/9 ECRA strains as prime and boosted with
AHSV 2/3/5/6/8 at day 21. Neutralizing antibodies
remained present in all monovalent vaccinated animals
for a minimum 24 weeks, although antibody titres peaked
immediately after receipt of the booster injection. For
cocktail vaccine trials, animals developed neutralizing
antibodies response to all 9 AHSV serotypes, demonstrat-
ing that a multivalent vaccine based on our ECRA AHSV
strains can be administered without the risk of cross
serotype interference.
Together, the data obtained from a broad range of orbi-
virus vaccines produced using RG systems have demon-
strated that they are as safe as subunit vaccines and
express viral proteins at the sites of viral infection in
animal hosts in a similar manner to that seen with the
natural viruses. Thus, the vaccines have a safety profile
similar to inactivated vaccines but with the cost advantage
and innate immunity triggering properties of attenuated
vaccines. The ECRA vaccine strains are grown in mam-
malian cells in large scale and there is no need to purify or
inactivate, both costly processes. It is important to note
that the production of the ECRA vaccines can be under-
taken at BSL-2 conditions, since no self-replication com-
petent materials are involved at any stage. Such a process
can dramatically decrease the cost in comparison to the
killed vaccine, which requires the generation of high
titres of pathogen in high containment laboratories with
subsequent inactivation and additional quality control
steps. Another advantage of the ECRA virus strains is
that a single strain can be used as the backbone of other
serotypes by reassortment, facilitating rapid development
of highly efficacious vaccine strains. Moreover, as ECRA
strains do not replicate fully in the animal host, only
express viral proteins once, the possibility of reassortment
or recombination with a co-infecting wild-type virus is
very low. The data shows that they can be administered as
a multivalent cocktail vaccine conferring protection
against all homologous virus infections without cross
serotype interference. Reverse genetics technology has
thus allowed the rapid and reliable generation of vaccines
against the threat of an outbreak of bluetongue disease
and AHS disease, regardless of the serotype involved. In
principle, any emerging serotype can be prepared rapidly
from the genomic material of the emerging strain to
produce a safe vaccine and a robust, protective immune
response.
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